Background: An in-frame deletion leading to the loss of a single glutamic acid residue in the protein torsinA (DE-torsinA) results in an inherited movement
Introduction
DYT1 dystonia is defined as ''early-onset generalized isolated dystonia''. 1 It is characterized by involuntary muscle contractions and abnormal postures, and caused by a mutation in the TOR1A gene (c.904_906delGAG/c.907_909delGAG; p.Glu302del/p.Glu303del) that results in deletion of a glutamic acid residue from the torsinA protein (DE-torsinA). [2] [3] [4] [5] [6] Patients with this autosomal dominant disorder are heterozygous for the mutation (TOR1A +/DE ). TorsinA belongs to the AAA+ family (ATPases associated with various cellular activities). 7 Its ATPase activity is regulated by proteins in the endoplasmic reticulum (ER) and nuclear envelope, 8 and is thought to contribute to diverse cellular processes, including the unfolding of proteins during their degradation, the disassembly of protein aggregates, and the disassembly of protein complexes. 7 Although the biochemical properties of torsinA have been identified, how it contributes to neuronal function in the brain remains elusive. Because the first dystonia gene locus to be identified was for DYT1 dystonia, it serves as a paradigm for the pathogenesis and pathophysiology of this debilitating neurological disorder. Knowledge of the subcellular distribution of torsinA is expected to provide insight into its function and the pathogenesis that occurs when it is mutated. According to a prevailing model for the localization and function of torsinA proteins, the wild-type form is present throughout the ER whereas the DE form is present in the nuclear envelope and causes abnormalities in its ultrastructure (reviewed, e.g., in Granata et al. 9 ). This proposed spatial redistribution of torsinA is thought to play a critical role in dystonia pathogenesis, because neuronal dysfunction can be caused by either a lack of wild-type torsinA or an accumulation of DE-torsinA in certain subcellular compartments. However, this model is based largely on studies in which expression of exogenous torsinA in host cells was forced (overexpression), and levels of the protein were much higher than in the endogenous state. As the total content of torsinA (wild-type plus DE-torsinA) in patient fibroblasts is similar to, or even slightly reduced from, that in normal subjects, [10] [11] [12] it is possible that the results from overexpression studies reflect a cellular state that is distinct from DYT1 dystonia. The objective of this article is to compare imaging-based results obtained from exogenous overexpression in host cells with those for endogenous expression in a natural context, and to identify issues that will need to be resolved in order to settle the question of endogenous torsinA localization.
Search strategy and selection criteria
PubMED searches of articles were carried out using the terms ''DYT1 dystonia,'' ''torsinA,'' ''TOR1A,'' ''distribution,'' or ''localization.'' No time limits were placed. The reference lists of the primary articles were also searched. Only mammalian studies reported in fulltext articles written in English were analyzed.
Consistent localization results with overexpression systems
In overexpression systems, the human torsinA genes are exogenously introduced into model animals or cells. The distribution of overexpressed torsinA is typically evaluated by one of three methods: 1) torsinA is tagged with a fluorescent protein (fluorescence tag, e.g., green fluorescent protein [GFP] , cyan fluorescent protein [CFP] ) and its fluorescence is detected; 2) torsinA is tagged with a non-fluorescent peptide (epitope-tag, e.g., myc-tag, V5-tag, polyhistidine-tag) and is detected by immunocytochemistry using an anti-tag antibody; or 3) untagged torsinA is overexpressed and detected by immunocytochemistry using an anti-torsinA antibody. Western blotting was used to measure the fold increase in the level of protein overexpression. The value has been reported as ,1.3 to 1.5, 13 ,1.3 to 2.3, 14 ,2 to 6, 15 in transgenic mice, and as high as ,2 to ,20, 16 or ,10 to 50 in some cultured cells. 17, 18 In studies where the Western blotting results were not quantified, the signals from endogenous protein were very weak or not detectable, in comparison to the overexpressed protein in cultured cells. [19] [20] [21] Overexpression studies have provided relatively consistent results (Table 1) . In Table 1 , the reported data are entered according to the host cell types, and these are broadly classified into cultured nonneuronal cells, cultured tumor cells of neuronal origin, cultured neurons, and neurons in situ. All of the host cells had a wild-type background. For the sake of highlighting the potential variations among individual reports, the entries for a particular cell type are grouped together only where exactly the same result regarding either the subcellular distribution of torsinA or its colocalization with organellar markers was reported by the same group of researchers. In the case of wild-type torsinA, overexpressed protein was localized mainly in the ER, resulting in diffuse cytoplasmic-or where the resolution was high enough tubular or reticular-staining. At the level of light microscopy, the ER domain was almost equivalent to the cytoplasmic domain. A minor component of the signal emanated from the nuclear envelope (which is contiguous with the ER), in a perinuclear, ring-like pattern around the nucleoplasm. In the case of DE-torsinA, by contrast, the overexpressed protein was present mainly at the nuclear envelope and/or in cytoplasmic inclusion bodies. A minor component was present in the ER. Notably, the distributions of wild-type and DE forms of torsinA were not specific to the host cell types used, to whether the cells examined were cultured or in brain slices (in situ), or to the brain regions analyzed. Rather the distributions corresponded to whether it was wild-type or DE-torsinA that was overexpressed. Thus the general conclusion from these findings was that the signature feature of DYT1 dystonia is the mislocalization of DE-torsinA.
Advantages of overexpression systems
Overexpression systems are widely used, in part because they make it possible to introduce recombinant forms of torsinA with modifications. Other advantages of overexpression systems include the following: a fluorescence tag can be used to reveal torsinA localization, and the intensity of the tag is much stronger than background noise (autofluorescence); an epitope-tag can be used to reveal torsinA localization, and it can be detected with antibodies with high specificity for antigens not normally present in tissue; and, when an anti-torsinA antibody is used in this context, the signal of the overexpressed protein will be well above the background noise or endogenous signal, even though its affinity for torsinA may be lower than those of anti-tag antibodies for their respective tags. These overexpression systems have advantages in addition to their usefulness in analyzing the subcellular localization of torsinA. For example, they have been used to identify interacting partners of torsinA (reviewed, e.g., in Warner et al. 22 ), to purify the torsinA protein, 8, 19 to measure the rate of turnover of torsinA protein, 23 to evaluate the effects of torsinA in specific types of neurons, 24 and to establish what effects torsinA has on cell biological processes such as the ER-and oxidative-stress responses, and the chaperoning of proteins (reviewed, e.g., in Bragg et al. 6 ).
Disadvantages of overexpression systems
Overexpression systems are associated with several general issues, including potentially violating balanced gene dosage, and affecting the folding of proteins, the assembly of protein complexes, and the regulation of downstream signaling. 25 In addition, overexpression systems have at least two disadvantages specific to the study of torsinA. One is that the distribution of torsinA is known to change depending on the expression level (Table 2) . When DE-torsinA expression is low, it is present in the nuclear envelope (e.g. two-to 10-fold increase from the endogenous level), whereas when its expression is high, it is preferentially localized to cytoplasmic inclusions (e.g. ,20-fold 23 Gordon et al., 73 Maric et al., 89 Martin et al. 98 
Cultured neurons
Mouse midbrain neurons (including substantia nigra, ventral tegmental area) increase from the endogenous level). 16 The fact that the expression level is a strong determinant of at least the DE-torsinA distribution pattern indicates that the localization would have to be extrapolated to estimate the distribution of torsinA proteins at the low, endogenous level. However, it is unclear how such extrapolation can be achieved and, even if it is possible, to what extent the extrapolated properties would reflect those of the endogenous proteins. As a side note, some exceptions to the consistent overexpression results have been reported. For example, DE-torsinA was mislocalized in the neuroblastoma cell line SH-SY5Y but not in the non-neuronal HeLa cell line 26 or in the neurons of transgenic mice overexpressing human DE-torsinA 14, 27 ( Table 1) . This phenomenon can be explained if the expression levels of wild-type and DE-torsinA were different in those studies. Another disadvantage of the overexpression systems is their dependence on the properties of the promoters used to express the transgenes (promoters in transgenic animals have been reviewed in Tassone et al., 28 Oleas et al., 29 and Richter and Richter
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). For instance, the commonly used human cytomegalovirus (CMV) major immediate-early promoter/enhancer is considered strong, but its effect is influenced by neuronal activity, with depolarization increasing its efficiency more than 90-fold. 31 Thus, expression will be low in neurons with weak spontaneous activity, and such activity may be masked by high expression in more active neurons. Moreover, different promoters demonstrate different tissue specificities and developmental expression profiles.
32
In summary, the results obtained from overexpression systems are mostly clear and consistent, albeit with a few exceptions. However, caution is needed in interpreting them, especially with respect to the subcellular localization of torsinA proteins, until such outcomes are reliably replicated at endogenous levels of expression.
Inconsistent localization results for endogenous torsinA
Endogenous torsinA has been detected by indirect immunocytochemistry. The primary anti-torsinA antibody is detected using a secondary antibody conjugated with a fluorescent probe (fluorophore) or an enzyme that synthesizes colored or electron-dense product. 33 For a partial list of torsinA antibodies, see Xiao et al. 34 In sharp contrast to the outcomes for overexpression systems, the reported distribution of the endogenous torsinA protein is fairly inconsistent (Table 3 ).
In the case of in vitro studies, the cytoplasmic distribution of wild-type torsinA was typically diffuse, but it was punctate in a pattern consistent with vesicle staining in immature neurons and neuron-like tumor In this article, ''perinuclear'' indicates ring-like staining of the nuclear envelope completely surrounding the nucleoplasm. ''Inclusions'' indicate intracellular, cytoplasmic inclusion bodies, except where intranuclear inclusion is specifically mentioned in Table 3 . The cytoplasmic inclusions were often located near cellular nuclei.
(-) indicates not tested. Table 1 includes results with human torsinA, except for one study that analyzed porcine torsinA (mentioned as such). Table 1 and Table 2 include both controlled and uncontrolled expression of the exogenous transgene.
In Tables 1-3 , the results are limited to the distributions of wild-type and DE-torsinA. They do not include other naturally occurring mutations or genetically engineered proteins. Results from experimental manipulations that could affect the torsinA distribution were not included. Such manipulations are, e.g., the cotransfection with non-torsinA transgene constructs, the induction of cellular stress and ischemic insults, and the pharmacological regulation of biological processes. Abbreviations and comments in Tables 1-3 39 In the fibroblasts of DYT1 dystonia patients, perinuclear staining was reported in one study 10 but was absent in others. 40, 41 Notably, staining of cytoplasmic inclusions was absent in all cases, consistent with findings from studies in fibroblasts from control subjects.
10, 40, 41 In the case of neurons in situ, the results were more variable than those described above. The majority of studies found that wild-type torsinA was distributed diffusely throughout the cytoplasm of the somata and proximal dendrites. However, the following patterns were also described: strong staining of axons and nerve terminals; [42] [43] [44] [45] strong staining of the neuropil without staining of somata or dendrites; 46 staining of the proximal dendrites of some but not all neurons; 47 and staining of the nucleoplasm. 47, 48 Of interest is the notion that the torsinA-positive domain of the neuron does not completely overlap with the ER. 49 Even after nucleoplasmic staining was excluded, the torsinA staining covered only a portion of the cytoplasm, 47, 48 suggesting that a non-ER compartment could be stained. In the brains of DYT1 dystonia patients, the distribution of torsinA protein was the same as in those from control subjects, i.e., a lack of staining of inclusions or the nuclear envelope, 44 ,49 although cytoplasmic inclusions were found in brainstem regions. 50 
Approaches to filling the gap
The discrepancies in the distribution results for exogenous and endogenous torsinA proteins mainly arise from variation in the reported distribution of endogenous torsinA. It is difficult to interpret the results of overexpression studies, given that the pattern or determinant of endogenous localization is not yet clear. The latter could reflect genuine variations in the biology of this protein, reflecting subtle differences and changes in torsinA expression. It is also possible that the subcellular distribution of torsinA differs by cell type, by brain region, by species, and/or developmental stage, and there may even be intrinsic variation among individuals. Furthermore, in the case of human brains, the levels of protein expression may be affected by how, and for how long, the subjects had experienced pathological stresses before death, because torsinA expression at both the mRNA 51 and protein 52 levels is regulated by insults.
Before discussing these interesting variations of biological importance, however, it should be stated that the more likely causes of variation are technical issues concerning specificity and efficiency in detecting endogenous torsinA. Identifying the sources of any technical complications will help explain the discrepancies in the observed distributions for exogenous and endogenous torsinA.
One potentially important challenge in comparing the data for the two types of expression is that the lower level of expression for endogenous torsinA will make it difficult to distinguish positive signals from background noise. Importantly, any factor that negatively influences the immunocytochemical detection procedures may affect interpretation. Thus, it will be particularly important to test whether each step in the immunocytochemical procedure is working properly and is optimized, in both in vitro and in situ studies, and at both the light and the electron microscopy levels. The following are ways that future studies can achieve such optimization, as suggested for immunocytochemical reports more generally. 33, [53] [54] [55] Firstly, it will be important to test primary antibodies for their specificity in binding to the antigen. The literature suggests at least five controls for general immunocytochemical procedures. [53] [54] [55] The first control is to manipulate expression of the antigen. Suggested approaches are genetic deletion in knock-out animals or downregulation by RNA interference. A variation of this test is to upregulate the antigen, for example, by overexpressing GFP-tagged antigen, and detecting this protein simultaneously by GFP fluorescence and immunocytochemistry using secondary antibody conjugated with a different fluorophore. 55 A drawback of this approach is that predominance of the overexpressed antigen can mask the specificity of a weak antibody. The second control is to preadsorb the antibody with the immunizing peptide. The third control is to compare the specificity of immunostaining at the cellular level to mRNA expression as assessed by in situ hybridization, taking into consideration that the two signals may be detected in different subcellular compartments. The fourth control is to test the antibody for overlap of its signal with that from other antibodies raised against non-overlapping epitopes of the same protein. The feasibility of this approach depends on the repertoire of available antibodies. The fifth control is to test the ability of the antibody to detect a single protein entity by Western blotting. However, in this case it needs to be born in mind that the proteins are ).
in different states with respect to their secondary, tertiary and quaternary structures when recognized by immunocytochemistry vs. Western blotting (denatured by sodium dodecyl sulfate, heat or reducing condition), and thus this test could produce irrelevant information. Controls of these types are especially important for polyclonal antibodies, given that they identify multiple epitopes in the antigen (torsinA), some of which could be shared with non-related proteins. Such non-specific binding is less likely to occur with monoclonal antibodies, for which the epitopes are specific peptide sequences that are not shared with other proteins. Secondly, it will likewise be vital to control secondary antibodies for their specificity in binding to a primary antibody of interest. A typical method is to omit the primary antibody, and examine whether the signal is eliminated. 53, 55 Omission of both the primary and secondary antibodies will establish to what extent the native tissue produces background noise, e.g., autofluorescence (''label control'' in Burry 55 ). Thirdly, other aspects of immunocytochemical procedures will also require careful optimization. These include: the concentration of the primary antibody (e.g., too high a concentration leads to non-specific staining 33 ); the type and duration of chemical fixation (e.g., one torsinA antibody was incompatible with procedures of cryo-immunoelectron microscopy 37 ); and the type of embedding medium (e.g., paraffin embedding under heat can reduce the antigenicity). These aspects are especially important for in situ studies, because the procedures typically take longer than those required for in vitro studies and are therefore more susceptible to artifacts caused by non-ideal conditions. For example, animal tissues are chemically fixed for a prolonged period of time, first by trans-cardiac perfusion with a fixative (perfusion fixation) for ,30 min, and second by immersion of the tissue in the same fixative (immersion post-fixation) for one to two days. In contrast, cultured cells are typically fixed (immersion fixation) for ,30 min only. If torsinA antigenicity is affected by the duration of fixation, the results can be variable depending on the protocols used in individual experiments. Lastly, not only the staining of samples, but also the imaging of signals can be affected by numerous factors. The first is optical resolution along the focal axis (in the z-direction). Resolution is limited to ,1 mm even when optical sectioning is carried out by confocal microscopy, and it is worse in the case of widefield microscopy. 56 Therefore, when paraffin sections (e.g., 3-mm thickness 57, 58 ) and floating sections (e.g., 50-mm thickness 59 ) are used, the signal detected at any focal plane will be affected by stray signal from adjacent structures in other focal planes. Some forms of super-resolution fluorescence imaging will suffer from the same problem in thick sections. This issue is best resolved when ultrathin sectioning is achieved physically (e.g., 50-200 nm). 60 Second, the level of the focal plane is important because of the poor z-resolution of light microscopy. Even a non-diffuse signal can look diffuse and be mistaken as ER-like if the focal plane is outside the target structure. Third, it is essential to keep the imaging parameters at the same values (e.g., intensity setting and exposure time). 55 Otherwise, increasing the detection sensitivity could inappropriately lead to the inclusion of background noise as positive signal, and to an incorrect interpretation such as a diffuse ERlike pattern. The influences of the technical aspects discussed above have not been extensively evaluated in the field of DYT1 dystonia, although considerable efforts have been made. These include using the torsinA knock-out tissue in immunostaining 61 71 The key to definitive resolution of torsinA localization will be to evaluate these parameters for each antibody using each protocol, and using each tissue of interest in a given species. We understand that these efforts will be labor-intensive, and also that it will not be feasible to use such controls in studying human brains. However, systematic evaluation in at least the cellular and animal models will produce reliable immunocytochemical data that can be compared qualitatively to that produced in overexpression studies.
Of note, although species-specific antibodies are available, 23, 73 one of the current challenges is that no antibody available can distinguish between the wild-type and DE-torsinA proteins. 11, 13, 39, 74, 75 The study of torsinA distribution will be significantly improved if antibodies or other tools capable of doing so are developed.
Conclusions
Knowledge of the subcellular distribution of torsinA will be critical for understanding how wild-type torsinA affects neuronal function, as well as how DE-torsinA leads to neuronal dysfunction. This information will help researchers narrow down the potential pathophysiological roles of torsinA in DYT1 dystonia. For this purpose, it will be important to reassess the prevailing model of torsinA distribution based on exogenous torsinA, after the endogenous distribution is reliably established. Such reassessments will be valuable regardless of the precise outcome. Should the endogenous and exogenous distributions match, torsinA mislocalization in the model will be reinforced as one of the key events in pathogenesis. Should they differ, it will indicate that DE-torsinA is mislocalized as a consequence of abnormally high expression. In this case the new results will be particularly important in providing novel insights into pathophysiological mechanisms. Even under such conditions, it should be emphasized that this article is not aimed at downplaying the value of overexpression studies. Such studies make it possible, for example, to modify the molecular structure of torsinA and to identify regulatory interacting partners. Nevertheless, at this point, it will be essential to establish whether overexpression studies truly reflect the roles of endogenous torsinA and the pathogenesis of DYT1 dystonia.
reports on non-mammalian models of DYT1 dystonia as well as to any authors whose work is not discussed here.
